A multi-institution comparison of mitoxantrone, etoposide, and cytarabine (MEC) vs. high-dose cytarabine and mitoxantrone (Ara-C Couplets) therapy for patients with relapsed or refractory (R/R) acute myeloid leukemia.

被引：0

作者：

Christian, Sonia

Patel, Pritesh Rajni

Griffin, Shawn

Agrawal, Vaibhav

Khan, Irum

Sweiss, Karen

Shergill, Ardaman

Konig, Heiko

Quigley, John G.

机构：

[1] Univ Illinois, Chicago, IL USA

[2] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.e19005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e19005

引用

页数：2

共 50 条

[31] Mitoxantrone and Etoposide with or without Intermediate-Dose Cytarabine for the Treatment of Patients with Primary Induction Failure or Relapsed Acute Myeloid Leukemia
Trifilio, Steven
Radamaker, Alfred
Newman, Diane
Coyle, Kathryn
Leuer, Katrin Carlson
Mehta, Jayesh
Altman, Jessica Kaplan
Frankfurt, Olga
Tallman, Martin S.
BLOOD, 2010, 116 (21) : 897 - 898
[32] Induction chemotherapy with high-dose cytarabine and mitoxantrone in elderly acute myeloid leukemia (AML) patients.
Ramanathan, Muthalagu
Cerny, Jan
Raffel, Glen
Walsh, William Vincent
Woda, Bruce
Miron, Patricia
Nath, Rajneesh
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[33] A phase Ib study of oral panobinostat (LBH589) in combination with cytarabine (ARA-C) and mitoxantrone (MT) as salvage therapy for refractory or relapsed acute myeloid leukemia (AML)
Krauter, J.
Ottmann, O. G.
Schlenk, R. F.
Schaich, M.
Bouscary, D.
Dombret, H.
Luedicke, F.
Weber, H. J.
Winiger, I. J.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[34] Therapy of acute myeloid leukemia in patients over 60 years of age with intermediate dose cytarabine, mitoxantrone, and etoposide.
Shepherd, JD
Nantel, SH
Toze, CL
Hogge, DE
Sutherland, HJ
Conneally, EA
Nevill, TJ
Horsman, DE
Makhija, S
Thierman, JG
Barnett, MJ
BLOOD, 1999, 94 (10) : 237B - 237B
[35] Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.
Karol, Seth E.
Alexander, Thomas
Das Gupta, Soumyasri
Pounds, Stanley B.
Canavera, Kristin
Klco, Jeffery M.
Lacayo, Norman James
Pui, Ching-Hon
Opferman, Joseph T.
Rubnitz, Jeffrey E.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[36] Randomized trial of GM-CSF and G-CSF following high-dose cytarabine and mitoxantrone chemotherapy for relapsed and refractory acute leukemia.
Baer, Maria R.
Ford, Laurie A.
Bundy, Brian N.
Tighe, Sheila M.
O'Loughlin, Kieran L.
Slack, James L.
Wetzler, Meir
Wallace, Paul K.
BLOOD, 2006, 108 (11) : 223B - 223B
[37] Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia -: An Eastern Cooperative Oncology Group Pilot Study
Tallman, MS
Lee, S
Sikic, BI
Paietta, E
Wiernik, PH
Bennett, JM
Rowe, JM
CANCER, 1999, 85 (02) : 358 - 367
[38] A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia
Karanes, C
Kopecky, KJ
Head, DR
Grever, MR
Hynes, HE
Kraut, EH
Vial, RH
Lichtin, A
Nand, S
Samlowski, WE
Appelbaum, FR
LEUKEMIA RESEARCH, 1999, 23 (09) : 787 - 794
[39] High dose cytarabine, mitoxantrone and L-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly
Ahmed, Tamjeed
Holwerda, Scott
Klepin, Heidi D.
Isom, Scott
Ellis, Leslie R.
Lyerly, Susan
Manuel, Megan
Dralle, Sarah
Berenzon, Dmitriy
Powell, Bayard L.
Pardee, Timothy S.
LEUKEMIA RESEARCH, 2015, 39 (09) : 945 - 949
[40] High Dose Cytarabine, Mitoxantrone and L-Asparaginase (HAMA) Salvage For Relapsed Or Refractory Acute Myeloid Leukemia (AML) In The Elderly
Ahmed, Tamjeed
Holwerda, Scott
Pardee, Timothy
Isom, Scott
Lyerly, Susan
Ellis, Leslie Renee
Manuel, Megan
Dralle, Sarah
Dmitriy, Berenzon
Klepin, Heidi D.
Powell, Bayard L.
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →